EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PLOD1 Drives Head and Neck Squamous Cell Carcinoma Progression Through P4HA2 ‐Mediated Activation of the FAK / PI3K / AKT / mTOR Axis

Yan-Ling Wu, Hui Bai, Chao Jiang, Yuping Zhang, Wan Liu, JunJie Hang iD, Ying Huang iD

Journal of Cellular and Molecular Medicine · 2026-07 · 30 (13)

DOI: 10.1111/jcmm.71275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 03.07.2026. Verfasst von Yan-Ling Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese …. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Squamous Cell Carcinoma of Head and Neck, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanming Project of Medicine in Shenzen Municipality, Shenzhen Science and Technology Innovation Program, Shenzhen Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Some subtypes of head and neck squamous cell carcinoma (HNSCC) exhibit aggressive progression and poor prognosis, underscoring the need for novel therapeutic targets. While procollagen‐lysine, 2‐oxoglutarate 5‐dioxygenase 1 (PLOD1) is implicated in tumour collagen remodelling, its functional role and regulatory mechanisms in HNSCC remain elusive. PLOD1 expression and clinical relevance were analysed using TCGA‐HNSC data, patient tissues and cell lines. Functional impacts were assessed via in vitro assays (CCK‐8, flow cytometry, Transwell) and in vivo xenograft models. Mechanistic insights were explored through co‐immunoprecipitation, Western blotting, bioinformatics and pharmacological inhibition. PLOD1 was significantly upregulated in HNSCC tissues and correlated with adverse clinical outcomes. In vitro, PLOD1 overexpression potentiated proliferation, invasion and cell cycle progression while suppressing apoptosis; PLOD1 knockdown elicited opposing effects. PLOD1 activated the FAK/PI3K/AKT/mTOR pathway and directly interacted with prolyl 4‐hydroxylase subunit alpha 2 (P4HA2). P4HA2 rescue reversed PLOD1 knockdown‐mediated suppression of oncogenicity and pathway activation. The FAK inhibitor Y15 abrogated PLOD1‐driven malignant phenotypes. In vivo, PLOD1 silencing inhibited tumour growth and reduced FAK/PI3K/AKT/mTOR phosphorylation. PLOD1 drives HNSCC progression by modulating P4HA2 and activating the FAK/PI3K/AKT/mTOR signalling cascade, positioning the PLOD1‐P4HA2 axis as a promising prognostic biomarker and therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktSquamous Cell Carcinoma of Head and NeckPhosphatidylinositol 3-KinasesProcollagen-Lysine, 2-Oxoglutarate 5-DioxygenaseHead and Neck NeoplasmsFocal Adhesion Kinase 1HumansAnimalsSignal TransductionMiceCell ProliferationCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticApoptosisMice, NudeFemaleMale

Stichwörter der Autor:innen

FAK/PI3K/AKT/mTOR signallingP4HA2PLOD1head and neck squamous cell carcinomaprognostic biomarker

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProcollagen-Lysine, 2-Oxoglutarate 5-DioxygenaseMTOR protein, humanFocal Adhesion Kinase 1

Autor:innen und Institutionen

  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen…
  • Department of Radiology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Radiation Oncology, The People's Hospital of Shenzhen Baoan District, The Second Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Department of Oncology, The Second Affiliated Hospital of Shenzhen University (People's Hospital of Shenzhen Baoan District), Shenzhen, Guang Dong, China.
  • Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhe…
  • Department of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong,…

ORCID-Profile: JunJie Hang, Ying Huang

Förderung

  • Sanming Project of Medicine in Shenzen Municipality
  • Shenzhen Science and Technology Innovation Program
  • Shenzhen Medical Research Fund

Zitieren

APA

Wu, Y. L., Bai, H., Jiang, C., Zhang, Y., Liu, W., Hang, J., & Huang, Y. (2026). PLOD1 Drives Head and Neck Squamous Cell Carcinoma Progression Through P4HA2 ‐Mediated Activation of the FAK / PI3K / AKT / mTOR Axis. Journal of Cellular and Molecular Medicine, 30(13). https://doi.org/10.1111/jcmm.71275

Vancouver

Wu YL, Bai H, Jiang C, Zhang Y, Liu W, Hang J, et al. PLOD1 Drives Head and Neck Squamous Cell Carcinoma Progression Through P4HA2 ‐Mediated Activation of the FAK / PI3K / AKT / mTOR Axis. Journal of Cellular and Molecular Medicine. 2026;30(13). doi:10.1111/jcmm.71275

BibTeX
@article{Wu2026,
  author = {Wu, Yan-Ling and Bai, Hui and Jiang, Chao and Zhang, Yuping and Liu, Wan and Hang, JunJie and Huang, Ying},
  title = {PLOD1 Drives Head and Neck Squamous Cell Carcinoma Progression Through P4HA2 ‐Mediated Activation of the FAK / PI3K / AKT / mTOR Axis},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {13},
  doi = {10.1111/jcmm.71275}
}
Kostenlos starten →